KPRX

Kiora Pharmaceuticals Inc. (KPRX) - Q1 2026 10-Q Summary

Business Context and Reporting Period

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing therapies for ophthalmic diseases. The primary assets include KIO-301 (a photoswitch for retinal degeneration) and KIO-104 (an inhibitor for retinal inflammation). This report covers the quarterly period ended March 31, 2026.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $0.23 million compared to Q1 2025, driven primarily by a decrease in interest income and a reduction in the non-cash benefit from the change in fair value of contingent consideration.
• Operating Expenses: Total operating expenses increased by $0.18 million. General and Administrative (G&A) expenses rose by $0.12 million due to higher personnel and professional service costs. Research and Development (R&D) expenses decreased by $0.41 million, largely due to lower preclinical costs and a decrease in collaboration credits (reimbursements) from partner Théa Open Innovation (TOI).
• Liquidity Position: Cash and cash equivalents increased significantly from $8.70 million at year-end 2025 to $10.96 million at March 31, 2026, despite operating cash outflows. This was supported by net cash provided by investing activities of $5.40 million, primarily from the maturity of marketable securities.
• Collaboration Credits: Collaboration credits (reimbursements from TOI) decreased by $0.73 million to $1.23 million, reflecting lower reimbursable R&D expenses for the KIO-301 program in the current quarter.

Outlook, Guidance, and Risks

• Liquidity Outlook: Management anticipates having sufficient cash to fund planned operations into late 2028. This projection includes $13.88 million in cash and short-term investments as of March 31, 2026, plus approximately $5.0 million in net proceeds from a private placement financing transaction completed in April 2026.
• Recent Financing: On April 6, 2026, the Company closed a private placement raising approximately $5.0 million. This included the issuance of common stock, pre-funded warrants, and tranche warrants exercisable upon strategic transactions or Phase 3 enrollment.
• Clinical Progress:
  • KIO-301: The ABACUS-2 Phase 2 trial for retinitis pigmentosa is ongoing, with enrollment beginning in Q2 2025 and dosing in Q3 2025. An exclusive option agreement with Senju Pharmaceutical for Asian rights was signed in May 2025 for a $1.25 million upfront fee.
  • KIO-104: A Phase 2 trial for retinal inflammation began enrollment in Q2 2025 with dosing in Q3 2025.
• Risks: The Company has incurred losses since inception and expects to continue doing so. Future capital requirements depend on clinical trial outcomes, regulatory approvals, and the ability to secure additional financing. Failure to raise capital could force delays or termination of development programs.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $18.88 million total liquidity (including April 2026 proceeds) to fund operations through late 2028, considering potential acceleration of clinical costs.
• Collaboration Revenue Recognition: Confirm the timing of revenue recognition for the $1.25 million Senju option fee (currently deferred) and the status of reimbursements from TOI for KIO-301 expenses.
• Warrant Dilution: Assess the potential dilution from the new tranche warrants issued in April 2026, which are exercisable upon specific strategic or clinical milestones.
• Contingent Consideration: Monitor the fair value adjustments of the $2.95 million contingent consideration liability related to prior acquisitions (Bayon and Panoptes), which impacts operating expenses.
• Impairment Status: Note that while a $4.6 million impairment was recorded in late 2025 for the KIO-104 program due to stock price decline, management concluded no further impairment was necessary as of March 31, 2026.